Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K. Strumberg D, et al. Among authors: heinig r. Br J Cancer. 2012 May 22;106(11):1722-7. doi: 10.1038/bjc.2012.153. Epub 2012 May 8. Br J Cancer. 2012. PMID: 22568966 Free PMC article. Clinical Trial.
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O. Mross K, et al. Among authors: heinig r. Clin Cancer Res. 2012 May 1;18(9):2658-67. doi: 10.1158/1078-0432.CCR-11-1900. Epub 2012 Mar 15. Clin Cancer Res. 2012. PMID: 22421192 Clinical Trial.
Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein.
Boettcher MF, Heinig R, Schmeck C, Kohlsdorfer C, Ludwig M, Schaefer A, Gelfert-Peukert S, Wensing G, Weber O. Boettcher MF, et al. Among authors: heinig r. Br J Clin Pharmacol. 2012 Feb;73(2):210-8. doi: 10.1111/j.1365-2125.2011.04083.x. Br J Clin Pharmacol. 2012. PMID: 21838789 Free PMC article. Clinical Trial.
Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.
Weber O, Willmann S, Bischoff H, Li V, Vakalopoulos A, Lustig K, Hafner FT, Heinig R, Schmeck C, Buehner K. Weber O, et al. Among authors: heinig r. Br J Clin Pharmacol. 2012 Feb;73(2):219-31. doi: 10.1111/j.1365-2125.2011.04064.x. Br J Clin Pharmacol. 2012. PMID: 21762205 Free PMC article.
Pupil reaction: a valid sensitive clinical biomarker for 5-HT compounds.
Boettcher M, Heinig R, Wensing G, Kuhlmann J. Boettcher M, et al. Among authors: heinig r. Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):246. doi: 10.1111/j.1742-7843.2005.pto960317.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 15733223 Free article. No abstract available.
63 results